Viral Inactivation Market Size, Share, Revenue and Forcast 2034
Global Viral Inactivation Market Growth, Size, Trends Analysis - By Product & Service, By Application, By End-use - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Jul-2025 | Report ID: HLCA25201 | Pages: 1 - 256 | Formats*: |
| Category : Healthcare | |||
Viral Inactivation Market Introduction and Overview
According to SPER Market Research, the Global Viral Inactivation Market is estimated to reach USD 2200.8 million by 2034 with a CAGR of 11.84%.
The report includes an in-depth analysis of the Global Viral Inactivation Market, including market size and trends, product mix, Applications, and supplier analysis. The Viral Inactivation Market was valued at USD XX billion in 2024 and is expected to grow at a CAGR of 11.84% from 2025 to 2034. This increase is the result of several interrelated factors that represent both expanding public health needs and scientific breakthroughs. Since viral infections are becoming more common and the dangers of viral contamination in biologics are becoming more widely recognized, viral safety has become a top priority in the research and manufacturing of vaccines, blood products, and therapeutic proteins.
By Product & Service Insights:
The kits and reagents category dominating in the market based on product & Service. The increase in biopharmaceutical and biotechnological businesses worldwide is responsible for this surge. New product introductions and increased development efforts have benefited the market. For instance, Croda Pharma recently unveiled Virodex TXR-1 and TXR-2 with the goal of increasing the efficacy of viral inactivation. The consistent rise in R&D expenditures has sped up medication development initiatives, increasing the need for trustworthy viral inactivation solutions and supporting the market's overall growth.
By Application Insights:
The vaccines and therapeutics segment the market leader with the biggest revenue share, according to application. The increasing investments in R&D fields like gene therapy and stem cell research, which have greatly aided in market expansion, are responsible for this supremacy. The need for inactivated vaccines has grown due to the increased incidence of cancer and other chronic diseases, which is bolstering the market's ongoing expansion.
By End-use Insights:
The pharmaceutical and biotechnology businesses segment dominated the market. This growth is ascribed to the continuous growth of biopharmaceutical and pharmaceutical companies, which has facilitated greater investment in the creation of novel medications and alternative therapies. To guarantee the safety and effectiveness of their products throughout the manufacturing cycle, these businesses frequently use bioreactors and a variety of viral inactivation approaches, including solvent detergent treatment, low pH methods, and other cutting-edge procedures.
Regional Insights:
North America dominated the viral inactivation industry with the biggest revenue share. Advanced infrastructure, the existence of large pharmaceutical and biotechnology companies, large R&D expenditures, and high government and private healthcare spending are the main drivers of this expansion.
Market Competitive Landscape:
The Viral Inactivation Market is dominated by established players such as Charles River Laboratories, Inc., Clean Cells, Cytiva (Danaher Corporation), Merck KGaA, Mettler Toledo, as well as a number of small and medium-sized companies. These market participants focused on, a mix of product development, strategic alliances, and entry into developing markets. In order to deliver cutting-edge viral inactivation technologies that improve safety, efficiency, and scalability—such as enhanced chemical reagents, filtration systems, and automated platforms—leading firms actively invest in research and development.
Recent Developments:
In June 2023, Texcell SA announced the opening of a testing center in North America. It is anticipated that this action will assist the business in improving the viral safety and clearance processes for biotherapeutics and medical devices.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Product & Service, By Application, By End-use |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | Charles River Laboratories, Inc., Clean Cells, Cytiva (Danaher Corporation), Merck KGaA, Mettler Toledo, Parker Hannifin Corp, Rad Source Technologies Inc, Sartorius AG, Texcell SA, Vironova AB |
- Global Viral Inactivation Market Size (FY 2021-FY 2034)
- Overview of Global Viral Inactivation Market
- Segmentation of Global Viral Inactivation Market by Product & Service (Kits and Reagents, Systems & Accessories, Services)
- Segmentation of Global Viral Inactivation Market by Application (Vaccines and Therapeutics, Stem Cell Products, Blood and Blood Products, Tissue/ Tissue Products, Cellular and Gene Therapy)
- Segmentation of Global Viral Inactivation Market by End-use (Pharmaceutical and Biotechnology Companies, CROs, Academic and Research Institutes, Others)
- Statistical Snap of Global Viral Inactivation Market
- Expansion Analysis of Global Viral Inactivation Market
- Problems and Obstacles in Global Viral Inactivation Market
- Competitive Landscape in the Global Viral Inactivation Market
- Details on Current Investment in Global Viral Inactivation Market
- Competitive Analysis of Global Viral Inactivation Market
- Prominent Players in the Global Viral Inactivation Market
- SWOT Analysis of Global Viral Inactivation Market
- Global Viral Inactivation Market Future Outlook and Projections (FY 2025-FY 2034)
- Recommendations from Analyst
1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
2. Research Methodology
- 2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
- 2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
- 2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
5. Market variable and outlook
- 5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
- 5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
- 5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
- 5.4. Heat Map Analysis
6. Competitive Landscape
- 6.1. Global Viral Inactivation Market Manufacturing Base Distribution, Sales Area, Product Type
- 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Viral Inactivation Market
7. Global Viral Inactivation Market, By Product & Service (USD Million) 2021-2034
- 7.1. Kits and Reagents
- 7.2. Systems & Accessories
- 7.3. Services
8. Global Viral Inactivation Market, By Application (USD Million) 2021-2034
- 8.1. Vaccines and Therapeutics
- 8.2. Stem Cell Products
- 8.3. Blood and Blood Products
- 8.4. Tissue/ Tissue Products
- 8.5. Cellular and Gene Therapy
9. Global Viral Inactivation Market t, By End-use (USD Million) 2021-2034
- 9.1. Pharmaceutical and Biotechnology Companies
- 9.2. CROs
- 9.3. Academic and Research Institutes
- 9.4. Others
10. Global Viral Inactivation Market, (USD Million) 2021-2034
- 10.1. Global Viral Inactivation Market Size and Market Share
11. Global Viral Inactivation Market, By Region, (USD Million) 2021-2034
- 11.1. Asia-Pacific
- 11.1.1. Australia
- 11.1.2. China
- 11.1.3. India
- 11.1.4. Japan
- 11.1.5. South Korea
- 11.1.6. Rest of Asia-Pacific
- 11.2. Europe
- 11.2.1. France
- 11.2.2. Germany
- 11.2.3. Italy
- 11.2.4. Spain
- 11.2.5. United Kingdom
- 11.2.6. Rest of Europe
- 11.3. Middle East and Africa
- 11.3.1. Kingdom of Saudi Arabia
- 11.3.2. United Arab Emirates
- 11.3.3. Qatar
- 11.3.4. South Africa
- 11.3.5. Egypt
- 11.3.6. Morocco
- 11.3.7. Nigeria
- 11.3.8. Rest of Middle-East and Africa
- 11.4. North America
- 11.4.1. Canada
- 11.4.2. Mexico
- 11.4.3. United States
- 11.5. Latin America
- 11.5.1. Argentina
- 11.5.2. Brazil
- 11.5.3. Rest of Latin America
12. Company Profile
- 12.1. Charles River Laboratories, Inc
- 12.1.1. Company details
- 12.1.2. Financial outlook
- 12.1.3. Product summary
- 12.1.4. Recent developments
- 12.2. Clean Cells
- 12.2.1. Company details
- 12.2.2. Financial outlook
- 12.2.3. Product summary
- 12.2.4. Recent developments
- 12.3. Cytiva (Danaher Corporation)
- 12.3.1. Company details
- 12.3.2. Financial outlook
- 12.3.3. Product summary
- 12.3.4. Recent developments
- 12.4. Merck KGaA
- 12.4.1. Company details
- 12.4.2. Financial outlook
- 12.4.3. Product summary
- 12.4.4. Recent developments
- 12.5. Mettler Toledo
- 12.5.1. Company details
- 12.5.2. Financial outlook
- 12.5.3. Product summary
- 12.5.4. Recent developments
- 12.6. Parker Hannifin Corp
- 12.6.1. Company details
- 12.6.2. Financial outlook
- 12.6.3. Product summary
- 12.6.4. Recent developments
- 12.7. Rad Source Technologies Inc
- 12.7.1. Company details
- 12.7.2. Financial outlook
- 12.7.3. Product summary
- 12.7.4. Recent developments
- 12.8. Sartorius AG
- 12.8.1. Company details
- 12.8.2. Financial outlook
- 12.8.3. Product summary
- 12.8.4. Recent developments
- 12.9. Texcell SA,
- 12.9.1. Company details
- 12.9.2. Financial outlook
- 12.9.3. Product summary
- 12.9.4. Recent developments
- 12.10. Vironova AB
- 12.10.1. Company details
- 12.10.2. Financial outlook
- 12.10.3. Product summary
- 12.10.4. Recent developments
- 12.11. Others
13. Conclusion
14. List of Abbreviations
15. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Viral Inactivation Market is projected to reach USD 2200.8 million by 2034, growing at a CAGR of of 11.84% during the forecast period.
Viral Inactivation Market grew in Market size from 2025. The Market is expected to reach USD 2200.8 million by 2034, at a CAGR of 11.84% during the forecast period.
Viral Inactivation Market CAGR of 11.84% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Viral Inactivation Market size is USD 2200.8 million from 2025 to 2034.
Viral Inactivation Market is covered By Product & Service, By Application, By End-use
The North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa is the highest Market share in the Viral Inactivation Market.
Charles River Laboratories, Inc., Clean Cells, Cytiva (Danaher Corporation), Merck KGaA, Mettler Toledo, Parker Hannifin Corp, Rad Source Technologies Inc, Sartorius AG, Texcell SA, Vironova AB
The report includes an in-depth analysis of the Global Viral Inactivation Market, including market size and trends, product mix, Applications, and supplier analysis.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
